NOVARTIS

KESIMPTA - Kesimpta Connect - Supporting patients video HCP

Prescribing information

Image

Image

Patient journey: How KesimptaConnect can support your patients

KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.[1]

For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).1

If you are viewing this video outside of a desktop app, please switch to landscape mode or click the expand button on the right-hand side of the video screen.

VIDEO

SmPC, summary of product characteristics.

Reference

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

Image

Safety profile

UK | March 2025 | FA-11213993

Adverse events should be reported. Reporting forms and information can be found at

www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:
https://www.pro.novartis.com/uk-en/medicines/neuroscience/kesimptaconnect/supporting-patients-video